Deleted ICD-10-PCS Code XW097M5 Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5

New Technology›Anatomical Regions›Introduction
  • Deleted — Not Valid for Claims
  • Valid FY 2021–2024
  • Deleted in FY 2025
CMS Source: CMS ICD-10-PCS code files FY 2021–2024 and the ICD-10-PCS conversion table.
Do not report XW097M5 for inpatient discharges on or after October 1, 2024. Claims with a deleted code are rejected. Use one of the replacement codes below.

XW097M5 is a deleted ICD-10-PCS code, removed from the code set effective October 1, 2024. It was valid for introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5 on inpatient discharges from October 1, 2020 through September 30, 2024, and later discharges must use a current code. The CMS conversion table maps it to 3E097GC.

Replacement Codes for XW097M5

The CMS ICD-10-PCS conversion table maps XW097M5 to this code. Confirm the choice against the procedure documentation and the code page's table.

  • 3E097GC Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening

Current Codes Starting With XW0

Active FY 2027 codes that share the first 3 characters of XW097M5 (same table).

  • XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
  • XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
  • XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
  • XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
  • XW023S6 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023T6 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023U6 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023V7 Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
  • XW023W7 Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
  • XW023Y7 Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
  • XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0330B Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0331B Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0336C Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
  • XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0337C Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

See the full XW0 table →

Code History

FY 2021AddedAdded to the ICD-10-PCS code setEffective October 1, 2020.
FY 2024Last fiscal year the code was validValid for discharges through September 30, 2024.
FY 2025DeletedRemoved from the ICD-10-PCS code setEffective October 1, 2024.

Questions About XW097M5

Is XW097M5 still a valid ICD-10-PCS code?

No. XW097M5 was deleted from ICD-10-PCS effective October 1, 2024, with the FY 2025 code set. It cannot be reported for inpatient discharges on or after that date.

What replaced XW097M5?

The CMS ICD-10-PCS conversion table maps XW097M5 to 3E097GC. Confirm it matches the procedure documentation before you use it; a conversion is a starting point, not an automatic substitution.

Can I still use XW097M5 for older discharges?

Yes, for inpatient discharges from October 1, 2020 through September 30, 2024. ICD-10-PCS codes are assigned by the code set in effect on the date of discharge, so a corrected or late claim for a discharge in that window still uses XW097M5.